People With Intellectual Or Developmental Disabilities Particularly Vulnerable To Effects Of Tobacco Use And Dependence

June 8, 2009

While tobacco use is an ongoing health hazard for the entire population, its consequences for people with developmental or intellectual disabilities can be especially severe. And the medical community often tends to overlook the tobacco-related burdens these people face. An extensive review of published research on this topic appears in the June edition of the journal Intellectual and Developmental Disabilities.

“This is too important an issue to ignore,” said Dr. Marc L. Steinberg, an assistant professor of psychiatry at the UMDNJ-Robert Wood Johnson Medical School and the article’s lead author. “Health care professionals often do not ask these individuals about tobacco use or exposure.”
Read the rest of this entry »

Advertisements

Combination Therapy For Type 2 Diabetes With Rosiglitazone (RECORD Study) Shows No Increase Of Cardiovascular Disease Or Death

June 6, 2009

The results of the RECORD study are reported in an article published Online First and in a future edition of The Lancet. The findings are presented at the same time at the American Diabetes Association (ADA) meeting in New Orleans, USA. They indicate that the use of rosiglitazone (Avandia) together with regular diabetes treatments (metformin or a sulfonylurea) to reduce blood glucose in type 2 diabetics does not raise the risk of cardiovascular disease or death. On the other hand, the research establishes that using rosiglitazone multiplies by more than two the risk of heart failure, and increases the risk of fracture, mostly in women.
Read the rest of this entry »


Combination Therapy For Type 2 Diabetes With Rosiglitazone (RECORD Study) Shows No Increase Of Cardiovascular Disease Or Death

June 6, 2009

The results of the RECORD study are reported in an article published Online First and in a future edition of The Lancet. The findings are presented at the same time at the American Diabetes Association (ADA) meeting in New Orleans, USA. They indicate that the use of rosiglitazone (Avandia) together with regular diabetes treatments (metformin or a sulfonylurea) to reduce blood glucose in type 2 diabetics does not raise the risk of cardiovascular disease or death. On the other hand, the research establishes that using rosiglitazone multiplies by more than two the risk of heart failure, and increases the risk of fracture, mostly in women.
Read the rest of this entry »


Spain’s Regional Extremadura Government Launches Electronic Prescription System With IBM

June 6, 2009

The Extremadura Regional Government of Spain and IBM (NYSE: IBM) have launched an electronic prescription system in 680 pharmacies in Extremadura, where health centres and pharmacies are now computerised and able to prescribe and dispense prescription medications electronically.

Electronic prescriptions make it easier for patients and doctors to monitor and control treatment. It also improves the quality of care as doctors have up to 30% more time for patient consultations, according to Extremadura Health Service.
Read the rest of this entry »


ZIOPHARM Presents Positive Data From Phase I Study Of Palifosfamide In Combination With Doxorubicin At ASCO

June 3, 2009

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced that it presented final data from a Phase I study of palifosfamide (ZymafosTM) in combination with doxorubicin at the 45th Annual American Society of Clinical Oncology (ASCO) meeting held in Orlando, FL, May 29th to June 2nd.

The Phase I trial of palifosfamide in combination with doxorubicin was fully enrolled with 13 patients, predominantly with soft tissue sarcoma and non-small cell lung cancer, and who had received a median of two prior therapies. Of 12 evaluable patients, there were 3 partial responses. Of the 8 patients with soft tissue sarcoma (STS) 75 percent had stable disease or better, with 2 having partial responses and 4 having prolonged stable disease. The median progression free survival (PFS) was 19 weeks.
Read the rest of this entry »


Recession Prompting Increase In Number Of People With HIV Seeking Public Services In California

June 3, 2009

The Los Angeles Times on Sunday examined how the recession is impacting people living with HIV in California. Brad Hare, medical director of University of California-San Francisco’s Positive Health Program at San Francisco General Hospital, said that people living with HIV who have lost their jobs and private health insurance are turning to public and nonprofit clinics for the first time and are responsible for a 12% increase this year in the clinic’s overall patient visits. He added that many of the patients he sees have gone months without receiving medical care. In addition, at the Los Angeles Gay and Lesbian Center, which also provides HIV treatment, the number of new patients has doubled over the last year, Thomas Soule, a spokesperson for the center, said. The Times also profiled a client of the center (Lin, Los Angeles Times, 5/31).

Read the rest of this entry »


Gene Network Sciences Announces Broad Cancer Collaboration With UCSF And Initial Results

June 1, 2009

Gene Network Sciences, Inc. (GNS) announced that it has entered into a research collaboration with the University of California San Francisco Cancer Center (UCSF) aimed at accelerating cancer research and drug development across several therapeutic areas. This collaboration will combine the clinical and research oncology expertise of UCSF with the computational expertise and supercomputer-driven REFS(TM) platform of GNS. Financial terms of the agreement were not disclosed.
Read the rest of this entry »